menu
    • menu
    [{"orgOrder":0,"company":"Bioxytran","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Galactomannan","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bioxytran","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bioxytran \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Bioxytran \/ Not Applicable"},{"orgOrder":0,"company":"Bioxytran","sponsor":"Triton Funds","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Financing","leadProduct":"Galactomannan","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bioxytran","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Chewable","sponsorNew":"Bioxytran \/ Triton Funds","highestDevelopmentStatusID":"10","companyTruncated":"Bioxytran \/ Triton Funds"},{"orgOrder":0,"company":"Bioxytran","sponsor":"Alke Research Private Limited","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Galactomannan","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bioxytran","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bioxytran \/ Alke Research Private Limited","highestDevelopmentStatusID":"10","companyTruncated":"Bioxytran \/ Alke Research Private Limited"},{"orgOrder":0,"company":"Bioxytran","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Galactomannan","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bioxytran","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Chewable","sponsorNew":"Bioxytran \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Bioxytran \/ Not Applicable"},{"orgOrder":0,"company":"Bioxytran","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Galactomannan","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bioxytran","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Chewable","sponsorNew":"Bioxytran \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Bioxytran \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Galactomannan

    Menu

    Galactomannan

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    MARKET PLACE

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Bioxytran

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Bioxytran

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Galactomannan

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Bioxytran's Oral Antiviral Drug to Enter Dose Optimization Clinical Trial for COVID-19

                            Details : ProLectin-M (galactomannan) is a precise chemistry based molecule that binds to galectin like receptors on the N terminal of S1 subunit of the Sars-CoV2 virus. It is being evaluated for COVID-19.

                            Brand Name : Prolectin-M

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            February 21, 2024

                            Lead Product(s) : Galactomannan

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Bioxytran

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Bioxytran

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Galactomannan

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Bioxytran Announces FDA Clearance of its IND Application for ProLectin-M in Clinical Trials

                            Details : ProLectin-M (galactomannan) is a chewable polysaccharide tablet for the treatment of mild to moderate and early stage COVID-19 Patients. The trial’s objective is to provide guidance for a 408 patient Phase III trial.

                            Brand Name : ProLectin-M

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            August 24, 2023

                            Lead Product(s) : Galactomannan

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Bioxytran

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Bioxytran

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Galactomannan

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : Alke Research Private Limited

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Bioxytran Initiates a Registrational Trial of Oral ProLectin-M for Mild to Moderate COVID-19 Patients

                            Details : ProLectin-M (galactomannan) is a chewable polysaccharide tablet for the treatment of mild to moderate and early stage COVID-19 Patients. The trial’s objective is to provide guidance for a 408 patient Phase III trial.

                            Brand Name : ProLectin-M

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            August 08, 2023

                            Lead Product(s) : Galactomannan

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : Alke Research Private Limited

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Bioxytran

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Bioxytran

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Galactomannan

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : Triton Funds

                            Deal Size : $0.5 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Bioxytran Expands Institutional Investor Base with an additional $500,000 Equity Investment

                            Details : The proceeds will help to start the dosage optimization study for mild to moderate COVID-19, which has already received the regulatory approval to proceed with dosing of ProLectin-M, an oral galectin antagonist that prevents the entry of the SARS-CoV-2 v...

                            Brand Name : ProLectin M

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            June 12, 2023

                            Lead Product(s) : Galactomannan

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : Triton Funds

                            Deal Size : $0.5 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Bioxytran

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Bioxytran

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Galactomannan

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Bioxytran Receives Approval to Optimize Dosage in COVID-19 Patients

                            Details : ProLectin-M having galactomannan, is a new class of antiviral drug designed to antagonize galectins implicated in inflammatory, fibrotic, and malignant diseases.

                            Brand Name : ProLectin-M

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            December 08, 2022

                            Lead Product(s) : Galactomannan

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth